Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | MMP2 | P08253 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GMNN | O75496 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21575869 | 1.00 | SHBG (0.48) | SHBGEPHX1TP53ALDH1A1HSD17B10 | |
| SCHEMBL8022524 | 1.00 | SHBG (0.48) | SHBGEPHX1TP53ALDH1A1HSD17B10 | |
| SCHEMBL5282 | 1.00 | — | — | |
| SCHEMBL5412 | 1.00 | SHBG (0.48) | SHBGEPHX1TP53ALDH1A1HSD17B10 | |
| SCHEMBL3335831 | 1.00 | SHBG (0.48) | SHBGEPHX1TP53ALDH1A1HSD17B10 | |
| SCHEMBL28542817 | 1.00 | SHBG (0.48) | SHBGEPHX1TP53ALDH1A1HSD17B10 | |
| SCHEMBL7739164 | 1.00 | SHBG (0.48) | SHBGEPHX1TP53ALDH1A1HSD17B10 | |
| Cyclohexane SCHEMBL5321429 | 1.00 | SHBG (0.48) | SHBGEPHX1TP53ALDH1A1HSD17B10 | |
| Water SCHEMBL9224817 | 0.97 | SHBG (0.46) | SHBGEPHX1TP53ALDH1A1HSD17B10 | |
| SCHEMBL140725 | 0.96 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109647199-A | A kind of preparation method of reverse osmosis membrane and thus obtained reverse osmosis membrane | 时代沃顿科技有限公司 | 2019-04-19 | — | — | CN | claimed |
| CN-105694028-A | Interfacial polymeric oil-phase reaction composition for preparing composite reverse osmosis membranes and use method thereof | 贵阳时代沃顿科技有限公司 | 2016-06-22 | — | — | CN | claimed |
| WO-2023235880-A1 | CD38 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. (US) | 2023-12-07 | — | — | WO | disclosed |
| WO-2023180237-A1 | METHOD AND COMPOUND | ATDBio Limited (GB) | 2023-09-28 | — | — | WO | disclosed |
| US-20230295172-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| US-11737349-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| US-11700765-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2023-07-11 | — | — | US | disclosed |
| CN-114682102-B | Reverse osmosis membrane and preparation method thereof | 沃顿科技股份有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-114682102-A | Reverse osmosis membrane and preparation method thereof | 沃顿科技股份有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-108440370-B | Inhibitors of viral replication | 鲁汶天主教大学 | 2021-07-30 | — | — | CN | disclosed |
| CN-112892249-A | Polyamide reverse osmosis membrane and preparation method thereof | 时代沃顿科技有限公司 | 2021-06-04 | — | — | CN | disclosed |
| US-5086071-A | Improved chemical stability and ppotent in vivo | TORAY INDUSTRIES, INC. (JP) | 1992-02-04 | — | — | US | disclosed |
| EP-0232776-B1 | 2,5,6,7-TETRANOR-4,8-INTER-M-PHENYLENE PGI2 DERIVATIVES | TORAY INDUSTRIES, INC. (JP) | 1990-10-24 | — | — | EP | disclosed |
| EP-0389162-A1 | 2,5,6,7-Tetranor-4,8-inter-m-phenylene PGI2 derivatives | TORAY INDUSTRIES, INC. (JP) | 1990-09-26 | — | — | EP | disclosed |
| EP-0365678-A1 | 2,5,6,7-TETRANOR-4,8-INTER-m-PHENYLENE PGI 2 DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 1990-05-02 | — | — | EP | disclosed |
| US-4880939-A | ANTISECRETORY AGENTS, HYPOTENSIVES, ANTICOAGULANTS | TORAY INDUSTRIES (JP) | 1989-11-14 | — | — | US | disclosed |
| US-4775692-A | ANTILIPEMIC, ANTICOAGULANT, HYPOTENSIVE, ANTISECRETORY AND ANTIULCER AGENT | TORAY INDUSTRIES, INC. (JP) | 1988-10-04 | — | — | US | disclosed |
| EP-0274064-A2 | 2,5,6,7-Tetranor-18,18,19,19-tetradehydro-4,8-inter-m-phenylene PGI2 derivatives | TORAY INDUSTRIES, INC. (JP) | 1988-07-13 | — | — | EP | disclosed |
| EP-0232776-A2 | 2,5,6,7-tetranor-4,8-inter-m-phenylene PGI2 derivatives | TORAY INDUSTRIES, INC. (JP) | 1987-08-19 | — | — | EP | disclosed |
| US-3992451-A | IN THE PRESENCE OF FREE RADICAL CATALYSTS, HYDROGEN CHLORIDE, AND CARBON MONOXIDE | UNIVERSAL OIL PRODUCTS COMPANY (US) | 1976-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11737349-B2 | Organic electroluminescent materials and devices | OCIAD2, OCIAD1, OTC | SHBG 2817/4885EPHX1 787/4885TP53 3701/4885 |
| US-11700765-B2 | Organic electroluminescent materials and devices | SOD1, L1CAM, MCM2 | SHBG 2620/4885EPHX1 528/4885TP53 3054/4885 |
| US-20230295172-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | SHBG 2685/4885EPHX1 1218/4885TP53 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.